Testosterone replacement therapy among elderly males: The Testim Registry in the US (TRiUS)

Clinical Interventions in Aging

Volumn 7, Issue , 2012, Pages 321-330

  Bhattacharya, Rajib K ^a   Khera, Mohit ^b   Blick, Gary ^c   Kushner, Harvey ^d   Miner, Martin M ^e  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Circle Medical LLC ^*  (United States)

^d Auxilium Pharmaceuticals   (United States)

^e MIRIAM HOSPITAL   (United States)

Author keywords

Elderly; Male hypogonadism; Testim; Testosterone gel; Testosterone replacement therapy; TRiUS registry

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGE DISTRIBUTION; AGED; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ANTHROPOMETRY; ARTICLE; BURN; CLINICAL TRIAL; COMPARATIVE STUDY; CORRELATION COEFFICIENT; DISEASE DURATION; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HYPOGONADISM; LABORATORY TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; ODOR; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PROSTATE CANCER; RHINOPHARYNGITIS; SIDE EFFECT; SKIN ALLERGY; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; UNITED STATES; WEIGHT GAIN; ADULT; AGE; COMORBIDITY; DRUG EFFECT; GEL; HORMONE SUBSTITUTION; MIDDLE AGED; PROSPECTIVE STUDY; QUALITY OF LIFE; REFERENCE VALUE; REGISTER; STATISTICS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COMORBIDITY; GELS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; QUALITY OF LIFE; REFERENCE VALUES; REGISTRIES; TESTOSTERONE; UNITED STATES; YOUNG ADULT;

EID: 84871703476     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S32036     Document Type: Article

References (45)

1. Araujo AB, O'Donnell AB, Brambilla DJ, etal. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:5920-5926.
2. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-731.
3. Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab. 2007;92: 549-555.
4. Araujo AB, Esche GR, Kupelian V, etal. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92:4241-4247.
5. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762-769.
6. Bhasin S, Cunningham GR, Hayes FJ, etal. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.
7. Laaksonen DE, Niskanen L, Punnonen K, etal. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27:1036-1041.
8. Traish AM, Saad F, Feeley RJ, Guay AT. The dark side of testosterone deficiency: III. Cardiovascular disease. J Andol. 2009;30:477-494.
9. AACE Hypogonadism Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract. 2002;8:439-456.
10. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry. 2004;61:162-167.
11. Kapoor D, Jones TH. Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? Drugs Aging. 2008;25:357-369.
12. Tuck SP, Francis RM. Testosterone, bone and osteoporosis. Front Horm Res. 2009;37:123-132.
13. Szulc P, Claustrat B, Marchand F, Delmas PD. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab. 2003;88:5240-5247.
14. Auyeung TW, Lee JS, Kwok T, etal. Testosterone but not estradiol level is positively related to muscle strength and physical performance independent of muscle mass: a cross-sectional study in 1489 older men. Eur J Endocrinol. 2011;164:811-817.
15. Maggio M, Ceda GP, Lauretani F, etal. Gonadal status and physical performance in older men. Aging Male. 2011;14:42-47.
16. Schaap LA, Pluijm SM, Smit JH, etal. The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin Endocrinol. 2005;63:152-160.
17. Orwoll E, Lambert LC, Marshall LM, etal. Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med. 2006;166:2124-2131.
18. Basaria S, Coviello AD, Travison TG, etal. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122.
19. Jones T. Clinical awareness and diagnosis of male hypogonadism. J Men's Health. 2009;5:S26-S34.
20. Miner MM, Khera M, Bhattacharya R, Blick G, Kushner H. Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency. Postgrad Med. 2011;123:17-27.
21. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the US (TRiUS). J Sex Med. 2011;8:3204-3213.
22. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Martin MM. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male. 2012;15:14-21.
23. Blick G, Khera M, Bhattacharya RK, Nguyen D, Kushner H, Miner MM. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS). Pain Med. 2012;13: 688-698.
24. Blick G, Miner MM, Khera M, Bhattacharya RK, Kushner H, Nguyen D. Testim Registry in the United States (TRiUS): baseline demographic and clinical parameters for HIV/AIDS patients with hypogonadism. Presented at: International Association of Physicians in AIDS Care, November 29-December 1, 2009, New Orleans, LA.
25. Blick G, Khera M, Miner M, Bhattacharya R, Kushner H, Nguyen D. Effect of testosterone replacement therapy (TRT) on sexual function, depression, and BMI in hypogonadal men with HIV/AIDS: analysis of a sub-cohort of the Testim Registry in United States (TRiUS). Presented at: XVIII International AIDS Conference (AIDS 2010), July 18-23, 2010, Vienna, Austria.
26. Bhattacharya RK, Khera M, Blick G, Kushner H, Nguyen D, Miner MM. Effect of 12months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). BMC Endocr Disord. 2011;11:18.
27. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Changes in prostate specific antigen in hypogonadal men after 12months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011;186:1005-1011.
28. Permpongkosol S, Tantirangsee N, Ratana-Olarn K. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints. J Sex Med. 2010;7:3765-3774.
29. Kenny AM, Kleppinger A, Annis K, etal. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58:1134-1143.
30. Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab. 2008;93:139-146.
31. Ottenbacher KJ, Ottenbacher ME, Ottenbacher AJ, Acha AA, Ostir GV. Androgen treatment and muscle strength in elderly men: A meta-analysis. J Am Geriatr Soc. 2006;54:1666-1673.
32. Shores MM, Kivlahan DR, Sadak TI, Li EJ, Matsumoto AM. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry. 2009;70:1009-1016.
33. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, etal. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299:39-52.
34. Ferrando AA, Sheffield-Moore M, Yeckel CW, etal. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282:E601-E607.
35. Srinivas-Shankar U, Roberts SA, Connolly MJ, etal. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95:639-650.
36. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88:2673-2681.
37. McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003;91:69-74.
38. Dean JD, Carnegie C, Rodzvilla J, Smith T. Long-term effects of Testim® 1% testosterone gel in hypogonadal men. Rev Urol. 2005;7:87-94.
39. Calof OM, Singh AB, Lee ML, etal. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451-1457.
40. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Andol. 2003;24:299-311.
41. Berges R, Oelke M. Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older. World J Urol. 2011;29:171-178.
42. Carson CC III, Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med. 2012;9:54-67.
43. Rice D, Brannigan RE, Campbell RK, etal. Men's health, low testosterone, and diabetes: individualized treatment and a multidisciplinary approach. Diabetes Educ. 2008;34(Suppl 5):97S-112S.
44. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci. 2003;58:618-625.
45. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899-906.